Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

Abstract:

:Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HER2-positive breast cancer. Patients with HER2-positive early breast cancer have to be treated with trastuzumab for one year in combination with and sequentially after chemotherapy. This requires that trastuzumab is intravenously infused over 30-90 minutes every 3 weeks for one year which is time-consuming for both the patient and the health care provider. Consequently, a subcutaneous formulation of trastuzumab using a recombinant human hyaluronidase has been developed. Recombinant human hyaluronidase transiently increases absorption and dispersion in the subcutaneous space of large therapeutic proteins, such as monoclonal antibodies, allowing subcutaneous administration of trastuzumab in about 5 minutes. Thus, subcutaneous trastuzumab could represent a new treatment option that could have benefit to both the patient and the health care system. This review focuses on the development of the subcutaneous trastuzumab formulation and analyzes clinical trials assessing the pharmacokinetics, efficacy, and safety of this new formulation.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Hamizi S,Freyer G,Bakrin N,Henin E,Mohtaram A,Le Saux O,Falandry C

doi

10.2147/OTT.S27733

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

89-94

issn

1178-6930

pii

ott-6-089

journal_volume

6

pub_type

杂志文章
  • The effects and mechanisms of a biosynthetic ginsenoside 3β,12β-Di-O-Glc-PPD on non-small cell lung cancer.

    abstract:Background:A biosynthetic ginsenoside, 3-O-β-D-glucopyranosyl-12-O-β-D-glucopyranosyl-dammar-24-ene-3β, 12β, 20S-triol (C3C12PPD), showed antitumor activity against many tumor cells in vitro, especially had better anti-lung cancer activity than Rg3 in vitro and in vivo. However, the effects and molecular mechanisms of ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S217039

    authors: Huang LL,Tang M,Du QQ,Liu CX,Yan C,Yang JL,Li Y

    更新日期:2019-09-09 00:00:00

  • Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma.

    abstract::The study is designed to explore the correlations of microvascular blood flow of contrast-enhanced ultrasound (CEUS) and hepatocyte growth factor (HGF)/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma (HCC). One hundred and eighteen patients pathological...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S113353

    authors: Zhuang PH,Xu L,Gao L,Lu W,Ruan LT,Yang J

    更新日期:2017-02-14 00:00:00

  • Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.

    abstract:PURPOSE:To evaluate whether the addition of two biological markers (MYC and BCL-2 protein overexpression) improves the stratification of high-risk patients with diffuse large B-cell lymphoma (DLBCL). METHOD:Seven risk factors were identified at diagnosis, and a maximum of 7 points were assigned to each patient. The pa...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S86093

    authors: Wang J,Zhou M,Xu JY,Chen B,Ouyang J

    更新日期:2015-09-18 00:00:00

  • MiR-486-5p Act as a Biomarker in Endometrial Carcinoma: Promotes Cell Proliferation, Migration, Invasion by Targeting MARK1.

    abstract:Background:miRNA expression acts as a potential biomarker in many diseases including endometrial carcinoma (EC). miR-486-5p dysregulation is observed in several tumor types, but the roles of miR-486-5p in EC are hardly ever studied. Objective:This study aimed to analyze the expression profile of miR-486-5p in tumor ti...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S246841

    authors: Zheng X,Xu K,Zhu L,Mao M,Zhang F,Cui L

    更新日期:2020-05-28 00:00:00

  • Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.

    abstract::Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes. CD123, the α-subunit of interleukin (IL)-3 receptor, is constantly overexpressed at the surface of tumoral cells. Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists o...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S228342

    authors: Beziat G,Ysebaert L

    更新日期:2020-06-09 00:00:00

  • Advances in the targeted therapy of liposarcoma.

    abstract::Liposarcoma (LPS) is the most common type of soft-tissue sarcoma. Complete surgical resection is the only curative means for localized disease; however, both radiation and conventional cytotoxic chemotherapy remain controversial for metastatic or unresectable disease. An increasing number of trials with novel targeted...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S72722

    authors: Guan Z,Yu X,Wang H,Wang H,Zhang J,Li G,Cao J,Teng L

    更新日期:2015-01-05 00:00:00

  • KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer.

    abstract:Background:KIF18B was identified as a potential oncogene by analysis of The Cancer Genome Atlas database. Materials and methods:We assessed KIF18B expression and explored its clinical significance in cervical cancer tissues. We have also evaluated the effects of KIF18B on cervical cancer cell proliferation, migration,...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S157440

    authors: Wu Y,Wang A,Zhu B,Huang J,Lu E,Xu H,Xia W,Dong G,Jiang F,Xu L

    更新日期:2018-03-28 00:00:00

  • Long Intergenic Non-Protein Coding RNA 519 Promotes the Biological Activities of Tongue Squamous Cell Carcinoma by Sponging microRNA-876-3p and Consequently Upregulating MACC1.

    abstract:Purpose:Long intergenic non-protein coding RNA 519 (LINC00519) promotes the development of lung squamous cell carcinoma. In this study, we detected the expression of LINC00519 in tongue squamous cell carcinoma (TSCC) and examined its clinical significance. Additionally, the regulatory effects of LINC00519 on behaviors ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S279798

    authors: Liu D,Zhao J,Wang H,Li H,Li Y,Qin W

    更新日期:2020-11-20 00:00:00

  • Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury.

    abstract:BACKGROUND/AIM:To elucidate the mechanism responsible for developing acute kidney injury in patients with diabetes mellitus, we also evaluated the issue of whether advanced glycation endproducts (AGEs) influence the expressions of multi antimicrobial extrusion protein (MATE1/SLC47A1) in tubular cells. MATERIALS AND ME...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S86743

    authors: Mizuno T,Sato W,Ishikawa K,Terao Y,Takahashi K,Noda Y,Yuzawa Y,Nagamatsu T

    更新日期:2015-07-10 00:00:00

  • Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report.

    abstract::Advanced gastric cancer (AGC) is difficult to treat with poor prognosis. Despite various possible treatments, the median survival time of such patients remains unsatisfactory. Therefore, new therapeutic approaches or combinations need to be further explored. We herein reported a case of a 54-year-old male patient who ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S221436

    authors: Yu S,Cai L,Lin F,Wu X,Zhang C,Liu X,Li W

    更新日期:2019-09-19 00:00:00

  • Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer.

    abstract:BACKGROUND:Permanent prostate brachytherapy (PPB) is an effective treatment choice for low and intermediate risk prostate cancer (PCa). However, the impact of PPB on tumor immune status is still poorly understood. This study aimed to assess the immune status in PCa patients before and at different time points after PPB...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S137491

    authors: Du E,Wang L,Li CY,Zhang CW,Qu YC,Liu RL,Xu Y,Yang K,Zhang ZH

    更新日期:2017-05-15 00:00:00

  • Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway.

    abstract::Forkhead box protein O1 (FOXO1) is a multifunctional transcription factor of the forkhead family. It may function as a tumor suppressor through its ability to regulate cellular events, including cell proliferation, apoptosis, and cell cycle control. As reported, FOXO1 is downregulated in papillary thyroid carcinoma (P...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S95395

    authors: Song HM,Song JL,Li DF,Hua KY,Zhao BK,Fang L

    更新日期:2015-12-01 00:00:00

  • lncRNA PCAT6 promotes non-small cell lung cancer cell proliferation, migration and invasion through regulating miR-330-5p.

    abstract:Background:Investigating the roles of lncRNA prostate cancer-associated transcript 6 (PCAT6) in modulating the growth and aggressiveness of non-small-cell lung carcinoma (NSCLC) cell. Method:The levels of PCAT6 in NSCLC tissues and cell lines were determined by quantitative real-time PCR assay. MTT as well as colony f...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S178597

    authors: Cui LH,Xu HR,Yang W,Yu LJ

    更新日期:2018-11-01 00:00:00

  • miR520a-3p suppresses cell proliferation and metastasis by inhibiting the p65-NFκB pathway in glioblastoma.

    abstract:Background:miR520a-3p has previously had its antitumorigenic role in various types of cancers revealed, and been predicted as a posttranscriptional regulator of the NFκB-subunit RELA gene. Thus, miR520a-3p could function in carcinogenesis through suppressing RELA. Methods:Expression of miR520a-3p and RELA mRNA was qua...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S208889

    authors: Zhang JQ,Hong B

    更新日期:2019-08-14 00:00:00

  • Prognostic value of FOXQ1 in patients with malignant solid tumors: a meta-analysis.

    abstract:BACKGROUND:Forkhead box Q1 (FOXQ1, also known as HFH1), a member of the forkhead transcription factor family, has been demonstrated to be overexpressed in multiple tumors and is thought to be an indicator of poor clinical outcomes. METHODS:A meta-analysis using qualified relevant literature was performed to evaluate t...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S130905

    authors: Cui X,Zhang J,Lv J,Yan Y,Liu X,Wang J,Lv Y,Zhang J

    更新日期:2017-03-23 00:00:00

  • The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.

    abstract:BACKGROUND:Vascular endothelial growth factor (VEGF) is a key mediator that plays an important role in angiogenesis, tumor growth, and tumor metastasis. The associations between five polymorphisms of VEGF (rs3025039, rs699947, rs10434, rs1570360, and rs2010963) and renal cell carcinoma (RCC) risk have been extensively ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S125965

    authors: Wang J,Shen C,Fu Y,Yu T,Song J

    更新日期:2017-03-21 00:00:00

  • Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study.

    abstract:Purpose:Bulky non-small cell lung cancer (NSCLC) is difficult to achieve effective local control by conventionally fractionated radiotherapy (CRT). The present work aims to evaluate the safety and efficacy of partial stereotactic ablative boost radiotherapy (P-SABR) in bulky NSCLC. Patients and methods:From December 2...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S159538

    authors: Bai Y,Gao XS,Qin SB,Chen JY,Su MM,Liu Q,Qin XB,Ma MW,Zhao B,Gu XB,Xie M,Cui M,Qi X,Li XY

    更新日期:2018-05-08 00:00:00

  • Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.

    abstract:Purpose:Circular RNAs (circRNAs) are emerging as promising biomarkers for various human malignancies. However, the application of circRNAs as non-invasive biomarkers in high-grade serous ovarian cancer (SOC) remains to be elucidated. Here, we aim to investigate the feasibility of using serum circSETDB1, a tumor-promoti...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S220700

    authors: Wang W,Wang J,Zhang X,Liu G

    更新日期:2019-09-11 00:00:00

  • Analysis of prostate bed motion using an endorectal balloon and cone beam computed tomography during postprostatectomy radiotherapy.

    abstract:BACKGROUND:The authors conducted this prospective study to analyze the amount of interfractional prostate bed motion (PBM) and quantify its components with the use of an endorectal balloon (ERB). METHODS:A total of 1,348 cone beam computed tomography images from 46 patients who underwent postprostatectomy radiotherapy...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S98112

    authors: Joo JH,Kim YJ,Kim YS,Cho YP,Lee HY,Jeong CY,Kwak J,Cho BC

    更新日期:2016-05-24 00:00:00

  • Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.

    abstract:Objective:This study aimed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT) plus nimotuzumab with or without concurrent chemotherapy (CCT) for patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Patients and methods:A total of 50 newly diagnosed patients with LA-NPC treated ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S151554

    authors: Huang J,Zou Q,Qian D,Zhou L,Yang B,Chu J,Pang Q,Wang K,Zhang F

    更新日期:2017-12-08 00:00:00

  • Cordycepin induces apoptosis in human pancreatic cancer cells via the mitochondrial-mediated intrinsic pathway and suppresses tumor growth in vivo.

    abstract:Background:Cordycepin, the main active ingredient of a traditional Chinese herbal remedy - extracted from Cordyceps sinensis - has been demonstrated as a very effective anti-inflammatory and antitumor drug. The present study investigated its antitumor effect on pancreatic cancer, a highly aggressive cancer with extreme...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S164670

    authors: Zhang Y,Zhang XX,Yuan RY,Ren T,Shao ZY,Wang HF,Cai WL,Chen LT,Wang XA,Wang P

    更新日期:2018-08-01 00:00:00

  • Sichong formula inhibits the proliferation and migration of human gastric cancer cells.

    abstract:Purpose:Traditional Chinese medicine (TCM) has gained increasing attention for the treatment of multiple chronic diseases, such as cancer. Here we aim to identify the antitumor activity of Sichong formula, a novel TCM, in human gastric cancer cells and investigate the underlying mechanisms. Methods:The AGS and MKN45 g...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S199605

    authors: Wang M,Tian Z,Zhu Y,Ding J,Li C,Zhou Y,Zhang Y

    更新日期:2019-07-16 00:00:00

  • Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.

    abstract::Patients with Lynch Syndrome (LS) are at high risk of developing colorectal cancer at an early age. Germline mutations in DNA mismatch repair genes and microsatellite instability are clear signatures of this autosomal dominant disorder. Here, we report the clinical history of a 38-year-old patient with LS-related meta...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S167645

    authors: Salman P,Panay S,Fernández R,Mahave M,Soza-Ried C

    更新日期:2018-10-23 00:00:00

  • Estrogen affects cell growth and IGF-1 receptor expression in renal cell carcinoma.

    abstract:Purpose:Both obesity and gender are important etiological factors in renal cell carcinoma (RCC) development, suggesting a pivotal role of sex hormone signaling pathway and insulin-like growth factor (IGF) family in RCC carcinogenesis. Here, we aimed to investigate the effect of estrogen on RCC growth and the possible i...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S172149

    authors: Sun L,Gao Z,Luo L,Tan H,Zhang G

    更新日期:2018-09-17 00:00:00

  • Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.

    abstract:BACKGROUND:The prognostic and predictive significance of the high-level microsatellite instability (MSI-H) phenotype in various malignancies is unclear. We describe the characteristics, clinical course, and outcomes of patients with MSI-H malignancies treated in a real-life hospital setting. PATIENTS AND METHODS:A ret...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S126905

    authors: Halpern N,Goldberg Y,Kadouri L,Duvdevani M,Hamburger T,Peretz T,Hubert A

    更新日期:2017-03-29 00:00:00

  • Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery.

    abstract:BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via proteinase-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase phosphorylat...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S105368

    authors: Ammendola M,Sacco R,Sammarco G,Piardi T,Zuccalà V,Patruno R,Zullo A,Zizzo N,Nardo B,Marech I,Crovace A,Gadaleta CD,Pessaux P,Ranieri G

    更新日期:2016-07-21 00:00:00

  • Analysis of Differential Expression Proteins of Paclitaxel-Treated Lung Adenocarcinoma Cell A549 Using Tandem Mass Tag-Based Quantitative Proteomics.

    abstract:Background:Paclitaxel is widely used in the treatment of cancer and has a good effect in the treatment of non-small cell lung cancer. The combination of TMT proteomics and bioinformatics is used to systematically analyze the molecular mechanism of paclitaxel in the treatment of lung adenocarcinoma A549 cell, which is h...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S259895

    authors: Zheng W,Xu S

    更新日期:2020-10-13 00:00:00

  • Onivyde for the therapy of multiple solid tumors.

    abstract::Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S105587

    authors: Zhang H

    更新日期:2016-05-20 00:00:00

  • Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study.

    abstract:Purpose:Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering from a high incidence of brain metastasis (BM). It is still controversial whether cranial radiotherapy could be delayed when the EGFR-tyrosine kinase inhibitors (TKIs) used as first-line therapy for EGFR-positive patients with BM. This...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S223216

    authors: An N,Wang H,Li J,Zhai X,Jing W,Jia W,Kong L,Zhu H,Yu J

    更新日期:2019-10-08 00:00:00

  • Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma.

    abstract:PURPOSE:The aim of this study was to evaluate an intravoxel incoherent motion (IVIM) model-based analysis of diffusion-weighted imaging (DWI) for assessing the response of hepatocellular carcinoma (HCC) to locoregional therapy. PATIENTS AND METHODS:Respiratory-gated DWI (b=0, 50, and 800 s/mm2) was retrospectively ana...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S113909

    authors: Mürtz P,Penner AH,Pfeiffer AK,Sprinkart AM,Pieper CC,König R,Block W,Schild HH,Willinek WA,Kukuk GM

    更新日期:2016-10-19 00:00:00